ARS Pharmaceuticals, Inc. — Director's Dealing 2022

May 4, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Silverback Therapeutics, Inc. (SBTX)
CIK: 0001671858
Period of Report: 2022-05-02

Reporting Person: Shawver Laura (Director, Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-05-02	Common Stock	A	68107	$0.00	Acquired	175502	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-05-02	Stock Option (right to buy)	$3.15	A	136214	Acquired	2032-05-01	Common Stock (136214)	Direct

Footnotes

F1: The shares being reported are being issued pursuant to restricted stock units, each one of which represents a contingent right to receive one share of the Issuer's common stock.

F2: The shares subject to the option will vest on May 2, 2023.